The following links lead to the full text from the respective local libraries:
Alternatively, you can try to access the desired document yourself via your local library catalog.
If you have access problems, please contact us.
11 results
Sort by:
In: Culture and customs of Latin America and the Caribbean
Mexico, with some 90 million people, holds a special place in Latin America. It is a large, complex hybrid, a bridge between North and South America, between the ancient and the modern, and between the developed and the developing worlds. Mexico's importance to the United States cannot be overstated. The two countries share historical, economic, and cultural bonds that continue to evolve. This book offers students and general readers a deeper understanding of Mexico's dynamism: its wealth of history, institutions, religion, cultural output, leisure, and social customs
In: Itoh , N & Bell , S E J 2017 , ' High dilution surface-enhanced Raman spectroscopy for rapid determination of nicotine in e-liquids for electronic cigarettes ' , The Analyst , vol. 142 , pp. 994-998 . https://doi.org/10.1039/C6AN02286C
The rise in popularity of electronic cigarettes and the associated new legislation concerning e-liquids has created a requirement for a rapid method for determining the nicotine content of e-liquids in the field, ideally at the point of sale. Here we have developed a rapid method based on surface-enhanced Raman spectroscopy (SERS) with Au colloids and an isotope-labeled nicotine (d4-nicotine) internal standard for the measurement/quantification of samples which contain 10s of mg mL−1 nicotine in a complex viscous matrix. This method is novel within the area of SERS because it uses high dilution (ca. 4000×) in the sample preparation which dilutes out the effects of the viscous glycerin/glycerol medium and any flavouring or colouring agents present but still allows for very accurate calibration with high reproducibility. This is possible because the nicotine concentration in the e-liquids (≤24 mg mL−1) is of several orders of magnitude above the working range of the SERS measurement. This method has been tested using a portable Raman spectrometer and a very large set of 42 commercial e-liquids to check that there is no matrix interference associated with different manufacturers/flavourings/colouring agents etc. Finally, as an alternative to determining the nicotine concentration by measuring peak heights in the spectra, the concentration was also estimated by comparing the sample spectra with those of a set of standard samples which were prepared at known concentrations and held in a spectral library file in the spectrometer. This simple approach allows the concentration to be estimated without any complex data analysis and lends itself readily to a handheld Raman system which is typically designed to carry out library searching using the internal software for materials identification. Library searching against standards correctly classified 41 of the 42 test liquids as belonging to the correct concentration group. This high dilution SERS approach is suitable for the analysis of sample types that have reasonably high concentrations of analytes but suffer from matrix problems, and it therefore has broad potential for applications across food, pharmaceutical and nutraceutical areas.
BASE
In: Alcohol and alcoholism: the international journal of the Medical Council on Alcoholism (MCA) and the journal of the European Society for Biomedical Research on Alcoholism (ESBRA), Volume 51, Issue 5, p. 609-614
ISSN: 1464-3502
In: The Manchester School, Volume 47, Issue 1, p. 33-62
ISSN: 1467-9957
In: Alcohol and alcoholism: the international journal of the Medical Council on Alcoholism (MCA) and the journal of the European Society for Biomedical Research on Alcoholism (ESBRA), Volume 51, Issue 3, p. 331-338
ISSN: 1464-3502
This Model United Nations Mock Session will showcase the work of the campus club and share with the other students the excitement of participating in a cooperative professional political atmosphere to find solutions to real world problems.
BASE
Iron is essential for many biological functions and iron deficiency and overload have major health implications. We performed a meta-analysis of three genome-wide association studies from Iceland, the UK and Denmark of blood levels of ferritin (N=246,139), total iron binding capacity (N=135,430), iron (N=163,511) and transferrin saturation (N=131,471). We found 62 independent sequence variants associating with iron homeostasis parameters at 56 loci, including 46 novel loci. Variants at DUOX2, F5, SLC11A2 and TMPRSS6 associate with iron deficiency anemia, while variants at TF, HFE, TFR2 and TMPRSS6 associate with iron overload. A HBS1L-MYB intergenic region variant associates both with increased risk of iron overload and reduced risk of iron deficiency anemia. The DUOX2 missense variant is present in 14% of the population, associates with all iron homeostasis biomarkers, and increases the risk of iron deficiency anemia by 29%. The associations implicate proteins contributing to the main physiological processes involved in iron homeostasis: iron sensing and storage, inflammation, absorption of iron from the gut, iron recycling, erythropoiesis and bleeding/menstruation. ; Participants in the INTERVAL randomised controlled trial were recruited with the active collaboration of NHS Blood and Transplant England (www.nhsbt.nhs.uk), which has supported field work and other elements of the trial. DNA extraction and genotyping was co-funded by the National Institute for Health Research (NIHR), the NIHR BioResource (http://bioresource.nihr.ac.uk/) and the NIHR [Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust] [*]. The academic coordinating centre for INTERVAL was supported by core funding from: NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024), UK Medical Research Council (MR/L003120/1), British Heart Foundation (SP/09/002; RG/13/13/30194; RG/18/13/33946) and the NIHR [Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust] [The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care]. A complete list of the investigators and contributors to the INTERVAL trial is provided in reference 73. The academic coordinating centre would like to thank blood donor centre staff and blood donors for participating in the INTERVAL trial. Professor John Danesh is funded by the National Institute for Health Research [Senior Investigator Award]. Will Astle, Joanna Howson and Tao Jiang are funded by the National Institute for Health Research [Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust]. Angela M Wood and Elias Allara are supported by EC-Innovative Medicines Initiative (BigData@Heart). Praveen Surendran is supported by a Rutherford Fund Fellowship from the Medical Research Council grant MR/S003746/1. This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome. The Novo Nordisk Foundation (NNF14CC0001 and NNF17OC0027594). The Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 115881 (RHAPSODY) (Karina Banasik and Søren Brunak). The Danish Administrative Regions; The Danish Administrative Regions' Bio- and Genome Bank; The authors thank all the blood banks in Denmark for both collecting and contributing data to this study. Danish Blood Donor Research Fund. Aarhus University, Copenhagen University Hospital Research Fund. Competing interests: Henrik Ullum received an unrestricted research grant form Novartis. Cristian Erikstrup received an unrestricted research grant from Abbott. Søren Brunak reports grants from Innovation Fund Denmark, grants from Novo Nordisk Foundation during the conduct of the study; and personal fees from Intomics A/S and Proscion A/S, outside the submitted work. For the authors who are affiliated with deCODE genetics/Amgen, we declare competing financial interests as employees.
BASE
Background: Low-risk limits recommended for alcohol consumption vary substantially across different national guidelines. To define thresholds associated with lowest risk for all-cause mortality and cardiovascular disease, we studied individual-participant data from 599 912 current drinkers without previous cardiovascular disease. Methods: We did a combined analysis of individual-participant data from three large-scale data sources in 19 high-income countries (the Emerging Risk Factors Collaboration, EPIC-CVD, and the UK Biobank). We characterised dose–response associations and calculated hazard ratios (HRs) per 100 g per week of alcohol (12·5 units per week) across 83 prospective studies, adjusting at least for study or centre, age, sex, smoking, and diabetes. To be eligible for the analysis, participants had to have information recorded about their alcohol consumption amount and status (ie, non-drinker vs current drinker), plus age, sex, history of diabetes and smoking status, at least 1 year of follow-up after baseline, and no baseline history of cardiovascular disease. The main analyses focused on current drinkers, whose baseline alcohol consumption was categorised into eight predefined groups according to the amount in grams consumed per week. We assessed alcohol consumption in relation to all-cause mortality, total cardiovascular disease, and several cardiovascular disease subtypes. We corrected HRs for estimated long-term variability in alcohol consumption using 152 640 serial alcohol assessments obtained some years apart (median interval 5·6 years [5th–95th percentile 1·04–13·5]) from 71 011 participants from 37 studies. Findings: In the 599 912 current drinkers included in the analysis, we recorded 40 310 deaths and 39 018 incident cardiovascular disease events during 5·4 million person-years of follow-up. For all-cause mortality, we recorded a positive and curvilinear association with the level of alcohol consumption, with the minimum mortality risk around or below 100 g per week. Alcohol consumption was roughly linearly associated with a higher risk of stroke (HR per 100 g per week higher consumption 1·14, 95% CI, 1·10–1·17), coronary disease excluding myocardial infarction (1·06, 1·00–1·11), heart failure (1·09, 1·03–1·15), fatal hypertensive disease (1·24, 1·15–1·33); and fatal aortic aneurysm (1·15, 1·03–1·28). By contrast, increased alcohol consumption was log-linearly associated with a lower risk of myocardial infarction (HR 0·94, 0·91–0·97). In comparison to those who reported drinking >0–≤100 g per week, those who reported drinking >100–≤200 g per week, >200–≤350 g per week, or >350 g per week had lower life expectancy at age 40 years of approximately 6 months, 1–2 years, or 4–5 years, respectively. Interpretation: In current drinkers of alcohol in high-income countries, the threshold for lowest risk of all-cause mortality was about 100 g/week. For cardiovascular disease subtypes other than myocardial infarction, there were no clear risk thresholds below which lower alcohol consumption stopped being associated with lower disease risk. These data support limits for alcohol consumption that are lower than those recommended in most current guidelines. Funding: UK Medical Research Council, British Heart Foundation, National Institute for Health Research, European Union Framework 7, and European Research Council.
BASE
The discovery of the enhancement of Raman scattering by molecules adsorbed on nanostructured metal surfaces is a landmark in the history of spectroscopic and analytical techniques. Significant experimental and theoretical effort has been directed toward understanding the surface-enhanced Raman scattering (SERS) effect and demonstrating its potential in various types of ultrasensitive sensing applications in a wide variety of fields. In the 45 years since its discovery, SERS has blossomed into a rich area of research and technology, but additional efforts are still needed before it can be routinely used analytically and in commercial products. In this Review, prominent authors from around the world joined together to summarize the state of the art in understanding and using SERS and to predict what can be expected in the near future in terms of research, applications, and technological development. This Review is dedicated to SERS pioneer and our coauthor, the late Prof. Richard Van Duyne, whom we lost during the preparation of this article. ; Funding is acknowledged from the European Research Council (ERC Advanced Grant No. 787510-4DBIOSERS to L.M.L.-M., ERC Advanced Grant No. 789104-eNANO to F.J.G.A., ERC Starting Grant No. 259432-MULTIBIOPHOT to J.K., ERC Consolidator Grant No. 772108-DarkSERS); the Department of Education of the Basque Government (Grant No. IT1164-19 to J.A.); the Spanish MINECO (CTQ2017-88648-R to R.A.-P., MAT2016-77809-R to I.P.-S. and J.P.-J.); the EPSRC (EP/P034063/1 to S.B., EP/L027151/1 to J.B., EP/L014165/1 to D.G. and K.F.); IDUN-Danish National Research Foundation (DNRF122) and Villum Fonden (Grant No. 9301) to A.B.; the National Research Foundation of Korea (Grant No. 2019R1A2C3004375 to J.B.); the German Science Foundation, DFG (SFB 1278 Polytarget (Project B4) to V.D., Grant No. SCHL 594/13-1 to S.S., Germany's Excellence Strategy (EXC 2089/1-390776260) to S.M.); the Federal Ministry of Education and Research, Germany (BMBF) (Grant InfectoGnostics 13GW0096F to D.C.-M. and J.P.); DARPA-16-35-INTERCEPT-FP-018 to L.F.; the UK BBSRC (Grant No. BB/L014823/1 to R.G.); the Department of Science and Technology (DST Nanomission Project SR/NM/NS-23/2016 to K.G.T.); the U.S. National Science Foundation (Grant No. CHE-1707859 to A.J.H., Center for Sustainable Nanotechnology CHE-1503408 (Centers for Chemical Innovation Program) to C.L.H., Center for Chemical Innovation Chemistry at the Space-Time Limit (CaSTL) CHE-1414466 to G.C.S. and R.P.V.D., Grant No. CHE-1807269 to K.A.W.); the Knut and Alice Wallenberg Foundation to M.K.; the Office of Naval Research (Grant No. N00014-18-1-2876 to N.A.K.); Royal Society of New Zealand Te Apa̅rangi to E.L.R. and B.A.; Singapore Ministry of Education, Tier 1 (RG11/18) to X.Y.L.; the Photoexcitonix Project in Hokkaido Univ., Japan, to K.M.; BioNano Health-Guard Research Center funded by the Ministry of Science and ICT (MSIT) of Korea as Global Frontier Project (Grant No. H-GUARD_2013M3A6B2078947) to J.-M.N.; NSFC of P. R. China (Grant No. 21705015 to Y.O., Grant No. 21633005 to B.R.); National Key R&D Program (2017YFA0206902) to C.X. This work was coordinated under the Maria de Maeztu Units of Excellence Program from the Spanish State Research Agency—Grant No. MDM-2017-0720. ; Peer reviewed
BASE
BACKGROUND: Low-risk limits recommended for alcohol consumption vary substantially across different national guidelines. To define thresholds associated with lowest risk for all-cause mortality and cardiovascular disease, we studied individual-participant data from 599 912 current drinkers without previous cardiovascular disease. METHODS: We did a combined analysis of individual-participant data from three large-scale data sources in 19 high-income countries (the Emerging Risk Factors Collaboration, EPIC-CVD, and the UK Biobank). We characterised dose-response associations and calculated hazard ratios (HRs) per 100 g per week of alcohol (12·5 units per week) across 83 prospective studies, adjusting at least for study or centre, age, sex, smoking, and diabetes. To be eligible for the analysis, participants had to have information recorded about their alcohol consumption amount and status (ie, non-drinker vs current drinker), plus age, sex, history of diabetes and smoking status, at least 1 year of follow-up after baseline, and no baseline history of cardiovascular disease. The main analyses focused on current drinkers, whose baseline alcohol consumption was categorised into eight predefined groups according to the amount in grams consumed per week. We assessed alcohol consumption in relation to all-cause mortality, total cardiovascular disease, and several cardiovascular disease subtypes. We corrected HRs for estimated long-term variability in alcohol consumption using 152 640 serial alcohol assessments obtained some years apart (median interval 5·6 years [5th-95th percentile 1·04-13·5]) from 71 011 participants from 37 studies. FINDINGS: In the 599 912 current drinkers included in the analysis, we recorded 40 310 deaths and 39 018 incident cardiovascular disease events during 5·4 million person-years of follow-up. For all-cause mortality, we recorded a positive and curvilinear association with the level of alcohol consumption, with the minimum mortality risk around or below 100 g per week. Alcohol consumption was roughly linearly associated with a higher risk of stroke (HR per 100 g per week higher consumption 1·14, 95% CI, 1·10-1·17), coronary disease excluding myocardial infarction (1·06, 1·00-1·11), heart failure (1·09, 1·03-1·15), fatal hypertensive disease (1·24, 1·15-1·33); and fatal aortic aneurysm (1·15, 1·03-1·28). By contrast, increased alcohol consumption was log-linearly associated with a lower risk of myocardial infarction (HR 0·94, 0·91-0·97). In comparison to those who reported drinking >0-≤100 g per week, those who reported drinking >100-≤200 g per week, >200-≤350 g per week, or >350 g per week had lower life expectancy at age 40 years of approximately 6 months, 1-2 years, or 4-5 years, respectively. INTERPRETATION: In current drinkers of alcohol in high-income countries, the threshold for lowest risk of all-cause mortality was about 100 g/week. For cardiovascular disease subtypes other than myocardial infarction, there were no clear risk thresholds below which lower alcohol consumption stopped being associated with lower disease risk. These data support limits for alcohol consumption that are lower than those recommended in most current guidelines. FUNDING: UK Medical Research Council, British Heart Foundation, National Institute for Health Research, European Union Framework 7, and European Research Council.
BASE